Northwest Biotherapeutics, Inc. announced that an application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).  The application builds upon the 3 licenses received for the Sawston facility in 2021. This application for a Manufacturer's license (MIA) represents the culmination of an additional year of intensive work, beyond the preparations over more than 2 years that were required for the applications for the initial licenses last year.

 The first license was received in September, 2021, from the Human Tissue Authority of the UK, and provided authorization for collection and storage of human tissues (such as the tumor tissue used to make the lysate for DCVax®-L products) and cells (such as the immune cells used to make DCVax-L).  The second and third licenses were received in December, 2021, from MHRA, and provided authorization for manufacturing cellular therapies for use in clinical trials and compassionate use ("Specials") cases, respectively. Preparations for this commercial license have included the creation of a further 50 standard operating procedures (SOPs) and policy and technical specification documents, validation of transport and shipping, and full validation and qualification of seven new pieces of equipment.  Each step in such validation and qualification processes incorporates user requirement specification, design qualification, installation/operational qualification and performance qualification.

 This takes many months for each item of equipment.  Additional controlled rate freezers were also procured, validated and qualified to expand the cryostorage capacity at the Sawston facility.